Abstract
Protein homeostasis is well accepted as the prerequisite for proper operation of various life activities. As the main apparatus of protein translation, ribosomes play an indispensable role in the maintenance of protein homeostasis. Nevertheless, upon stimulation of various internal and external factors, malfunction of ribosomes may be evident with the excessive production of aberrant proteins, accumulation of which can result in deleterious effects on cellular fate and even cell death. Ribosomopathies are characterized as a series of diseases caused by abnormalities of ribosomal compositions and functions. Correspondingly, cell evolves several ribosome quality control mechanisms in maintaining the quantity and quality of intracellular ribosomes, namely ribosome quality control system (RQCS). Of note, RQCS can tightly monitor the entire process from ribosome biogenesis to its degradation, with the capacity of coping with ribosomal dysfunction, including misassembled ribosomes and incorrectly synthesized ribosomal proteins. In the current literature review, we mainly introduce the RQCS and elaborate on the underlying pathogenesis of several ribosomopathies. With the in-depth understanding of ribosomal dysfunction and molecular basis of RQCS, therapeutic strategy by specifically targeting RQCS remains a promising option in treating patients with ribosomopathies and other ribosome-associated human diseases.
Introduction
Ribosomes are complex, stable organelles essential for life, yet they are not immortal. While traditional research has focused on how cells handle aberrant proteins, a new paradigm is emerging: the Eukaryotic Ribosome Quality Control System (RQCS). This holistic surveillance network shifts the focus from the products of translation to the integrity of the "machines" themselves.
As shown in the timeline above, the field has evolved from identifying simple recycling factors in the 1970s to discovering complex mammalian receptors like NUFIP-1 in 2018. This review synthesizes decades of research to define the RQCS as a critical safeguard against "ribosomopathies"—diseases caused by defective ribosomal components.
The RQCS Framework
The authors categorize the RQCS into four distinct stages of surveillance that monitor the ribosome throughout its entire life cycle:
- Biogenesis Surveillance: This stage monitors the assembly of ribosomal RNA (rRNA) and ribosomal proteins (RPs) within the nucleolus, ensuring that only correctly formed subunits proceed.
- Transportation Quality Control: Dedicated chaperones escort RPs to assembly sites, preventing premature aggregation or degradation.
- Ribosome Recycling: When translation stalls due to stressors or mRNA defects, factors like ZNF598 and RACK1 detect "ribosome collisions."
As illustrated in the pathway diagram, these collisions trigger the splitting of the ribosome into its Large Subunit (LSU) and Small Subunit (SSU). The stuck machinery is disassembled, and the components are either recycled or targeted for degradation via the RQC complex.
- Degradation Pathways: Faulty parts are disposed of via the proteasome (for individual proteins) or specialized autophagy, known as "ribophagy" (for whole ribosomes).
Clinical Implications and the "Ribosomopathy Paradox"
A critical insight of the RQCS is the link between ribosomal stress and the tumor suppressor p53. When assembly fails, free ribosomal proteins (e.g., RPL5, RPL11) accumulate and bind to MDM2, which normally inhibits p53. This "hijacking" activates p53, leading to cell cycle arrest or apoptosis—explaining why many ribosomopathies, such as Diamond-Blackfan anemia, initially present with bone marrow failure.
Furthermore, the "ribosomopathy paradox" explains how diseases characterized by reduced ribosome function (hypoproliferation) can transition into aggressive cancers (hyperproliferation). Deletions of quality control genes like RPL5 are found in a significant percentage of glioblastomas and melanomas, suggesting that the loss of these surveillance mechanisms is a major driver of genomic instability.
Conclusion and Future Directions
While our understanding of the RQCS has grown significantly, gaps remain. Much of our current knowledge is derived from yeast models, and the complexities of mammalian RQCS—particularly the selective degradation of the small 40S subunit—remain under-researched. Future therapeutic strategies may involve small molecules designed to stabilize mutant ribosomal proteins or artificially trigger the degradation of toxic ribosomes in aging cells, offering a new frontier for precision medicine in neurodegeneration and oncology.
Summary updated